Navigation Links
Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

CRANBURY, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will host a live conference call and webcast today, October 29, 2010 at 8:30 a.m. Eastern Time to discuss the Company's exclusive worldwide agreement with GlaxoSmithKline PLC to develop and commercialize Amigal (migalastat HCl) for the treatment of Fabry disease.

Interested participants and investors may access the conference call today at 8:30 a.m. Eastern Time by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. Eastern Time. Access numbers for this replay are 800-642-1687 (U.S./Canada) and 706-645-9291 (international); participant code 20951935.

A live audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases.  The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and CNS diseases.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
2. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
3. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
4. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
5. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
6. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
7. Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
8. Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
10. Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
11. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, LLC ... Pharmaceutical Specialties, Inc. ("PSI").  The combination of Texas ... Georgia -based PSI bring together both company,s clinical expertise ... and payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
(Date:12/2/2016)... Texas (PRWEB) , ... December 02, 2016 , ... Yisrayl ... that delves into how this current generation fits into Bible Prophecy. Yisrayl says this ... various facts pointing to this conclusion, showing how the details line up exactly with ...
Breaking Medicine News(10 mins):